HBV + C295 ISS-PMXB VACCINE IN BABOONS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本实验的目的是评估由C295-PMXB和乙肝表面抗原组成的新配方的剂量效应。本实验将有助于确定C295-PMXB在成年狒狒体内增强乙肝病毒抗原免疫原性的最佳剂量。本研究将由4组组成，每组5只动物。本实验将有助于确定C295 ISS-PMXB是否能增强对乙肝表面抗原的免疫应答，以及C295 ISS-PMXB增强免疫应答的最佳剂量。这种新的乙肝疫苗(乙肝病毒+C295 ISS-PMXB)可能对社会有益，因为它可以改善对乙肝表面抗原的应答，特别是在对目前批准的乙肝疫苗反应较差的人。C295 ISS-PMXB制剂(1000克C295)以前曾与Prevnar疫苗一起在狒狒身上进行过测试(正在进行的研究952-PC-0)。然而，C295 ISS-PMXB配方与乙肝疫苗抗原的结合从未在狒狒身上进行过测试。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to assess the dose response of a new formulation consisting of C295-PMXB in combination with HBV surface antigen. This experiment will help determine the optimal dose of C295-PMXB for increased immunogenicity of HBV antigen in adult baboons. This study will consist of 4 groups of 5 animals per group. This experiment will help determine if C295 ISS-PMXB can enhance the immune response to HBV surface antigen, and the optimal dose of C295 ISS-PMXB for enhanced immune response in baboons. This new HBV vaccine (HBV+ C295 ISS-PMXB) may be beneficial to society, since it could improve responses to HBV surface antigen, especially in poor responders to currently approved hepatitis B vaccines. C295 ISS-PMXB formulation (1000 ?g C295) has been previously tested in baboons in combination with Prevnar vaccine (ongoing study 952-PC-0). However, the C295 ISS-PMXB formulation in combination with HBV vaccine antigen has never been tested in baboons.